^
Association details:
| Biomarker: | BAP1 negative |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
Published date:
01/27/2021
Excerpt:
Rucaparib in patients with BAP1-negative or BRCA1-negative mesothelioma met the prespecified criteria for success, showing promising activity with manageable toxicity...Ten (38%) of 26 patients were BAP1 negative and BRCA1 negative, 23 patients (89%) were BAP1 negative, and 13 patients (50%) were BRCA1 negative...Disease control rate at 12 weeks was 58% (95% CI 37–77; 15 of 26 patients), and at 24 weeks was 23% (9–44; six of 26 patients).
DOI:
10.1016/S2213-2600(20)30390-8
Trial ID:
